Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 4 1Phase 3 1Phase 1 1

Status

Completed 6Recruiting 5Withdrawn 2Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 28Cisplatin 28Carboplatin 27Capecitabine 27camrelizumab 25Nivolumab 24apatinib 23Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 19Drug Therapy 18Immunotherapy, Adoptive 17pembrolizumab 16Docetaxel 16Bevacizumab 16Dexamethasone 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12Fluorouracil 11130-nm albumin-bound paclitaxel 11anlotinib 10Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Ramucirumab × Clear all
NCT03995017 2023-02-01

RiME

University of Kansas Medical Center

Phase 1/2 Unknown
34 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT04888663 2021-05-21

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Yonsei University

Phase 1/2 Unknown
50 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡